AstraZeneca Prostate Cancer, Generalized Myasthenia Gravis Treatments Get Approval in Japan
24 August 2023 - 8:58AM
Dow Jones News
By Michael Susin
AstraZeneca's prostate-cancer treatment Lynparza has been
approved in Japan, while Soliris has been approved for expanded use
to treat generalized myasthenia gravis, the company said
Thursday.
The Anglo-Swedish pharma giant said Lynparza, which is being
jointly developed with Merck & Co., has been approved in
combination with abiraterone and prednisolone for the treatment of
metastatic castration-resistant prostate cancer.
The approval was based on a late-stage study, which showed that
the combination reduced the risk of disease progression or death by
77% when compared with the abiraterone treatment alone.
In a separate statement, AstraZeneca said Soliris has been
approved in Japan to be used for the treatment of generalized
myasthenia gravis in pediatric patients under certain
conditions.
The treatment is the first and only targeted therapy approved
for the treatment of children and adolescents with the condition in
the country.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
August 24, 2023 02:43 ET (06:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
